HealthStream

Valuation Analysis

About the Company

HealthStream en bref

HealthStream (HSTM) is currently trading at 22,38 € with a market capitalization of 654 M €. The trailing P/E ratio stands at 38.27x, with a forward P/E of 29.64x. The 52-week range spans from 17,02 € to 25,86 €; the current price is 13.5% below the yearly high. Year-over-year revenue growth stands at +10.5%. The net profit margin stands at 6.39%.

💰 Dividende

HealthStream pays an annual dividend of 0,11 € per share, representing a yield of 0.51%. The payout ratio stands at 19.1%.

📊 Avis des analystes

2 analystes évaluent HealthStream (HSTM) au consensus : None. L'objectif de cours moyen est de 27,93 €, soit un potentiel de +24.8% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,94 € à 34,91 €.

HealthStream : la thèse d'investissement en détail

HealthStream (HSTM) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 10.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 42.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 64.89%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 3, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 29.64x is meaningfully below the trailing 38.27x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 24.8% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy HealthStream?

Compare top-rated brokers — low fees, trusted providers, fully regulated.